Will curcumin nanosystems be the next promising antiviral alternatives in COVID-19 treatment trials?

The COVID-19 has become of striking interest since the number of deaths is constantly rising all over the globe, and the search for an efficient treatment is more urgent. In light of this worrisome scenario, this opinion review aimed to discuss the current knowledge about the potential role of curcu...

Full description

Saved in:

Bibliographic Details
Published in:	Biomedicine & pharmacotherapy Vol. 139; p. 111578
Main Authors:	Dourado, Douglas, Freire, Danielle T., Pereira, Daniel T., Amaral-Machado, Lucas, N. Alencar, Éverton, de Barros, André Luís Branco, Egito, E. Sócrates T.
Format:	Journal Article
Language:	English
Published:	France Elsevier Masson SAS 01-07-2021 Published by Elsevier Masson SAS Elsevier
Subjects:	Animals Antiviral Agents - therapeutic use Clinical Trials as Topic Coronavirus COVID-19 Drug Treatment Curcuma longa Curcumin - therapeutic use Drug Delivery Systems Humans Nanomedicine Nanotechnology Natural products Review SARS-CoV-2 SARS-CoV-2 Coronavirus Curcuma longa Natural products Nanotechnology
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The COVID-19 has become of striking interest since the number of deaths is constantly rising all over the globe, and the search for an efficient treatment is more urgent. In light of this worrisome scenario, this opinion review aimed to discuss the current knowledge about the potential role of curcumin and its nanostructured systems on the SARS-CoV-2 targets. From this perspective, this work demonstrated that curcumin urges as a potential antiviral key for the treatment of SARS-CoV-2 based on its relation to the infection pathways. Moreover, the use of curcumin-loaded nanocarriers for increasing its bioavailability and therapeutic efficiency was highlighted. Additionally, the potential of the nanostructured systems by themselves and their synergic action with curcumin on molecular targets for viral infections have been explored. Finally, a viewpoint of the studies that need to be carried out to implant curcumin as a treatment for COVID-19 was addressed. [Display omitted] •Curcumin inhibits SARS-CoV-2 Mpro better than several marketed drugs in silico.•Curcumin blocks virus entry on cells via S protein and ACE II receptor.•Nanoparticles themselves present antiviral potential against SARS-CoV-2.•Antiviral synergism may be achieved between curcumin and nanoparticles.•Further studies must attest curcumin-NPs efficiency and safety.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
ISSN:	0753-3322 1950-6007 1950-6007
DOI:	10.1016/j.biopha.2021.111578